US
CA
NZ
UK
AU
IND
Last update at 2025-05-16T16:57:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Is Atai Life Sciences (ATAI) the Best German Stock to Buy According to Hedge Funds?
Wed 02 Apr 25, 07:35 PMatai Life Sciences Announces Pricing of Public Offering of Common Shares
Thu 13 Feb 25, 03:47 AMatai Life Sciences Announces Proposed Public Offering of Common Shares
Wed 12 Feb 25, 09:01 PMBillionaire Lee Cooperman Says The Market Is Expensive But Elevance Health, Inc. (ATAI) Is Cheap
Sun 25 Aug 24, 08:22 PM3 Dirt-Cheap Drug Developers With Blockbuster Potential
Thu 11 Jul 24, 11:00 AMWeekly Roundup on the Cannabis Sector & Psychedelic Sector
Mon 08 Aug 22, 11:00 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -135.18200M | -136.60100M | -101.81300M | -17.47400M |
| Minority interest | -5.03200M | 6.44M | 4.55M | 1.03M |
| Net income | -141.41100M | -132.61200M | -102.11800M | -17.47600M |
| Selling general administrative | 70.35M | 92.75M | 80.73M | 5.09M |
| Selling and marketing expenses | - | - | - | - |
| Gross profit | 0.23M | 20.38M | - | - |
| Reconciled depreciation | 0.17M | 0.05M | 0.02M | 0.00600M |
| Ebit | -144.78700M | -135.80500M | -104.16200M | 1.57M |
| Ebitda | -144.07300M | -104.84500M | -98.46700M | 1.58M |
| Depreciation and amortization | 0.71M | 30.96M | 5.70M | 0.00600M |
| Non operating income net other | -6.40100M | - | - | - |
| Operating income | -144.78700M | -135.80500M | -104.16200M | 1.57M |
| Other operating expenses | 144.66M | 140.70M | 92.14M | 8.17M |
| Interest expense | 1.92M | 66.91M | 71.05M | 15.71M |
| Tax provision | 6.23M | -3.98900M | 0.30M | 0.00200M |
| Interest income | 0.55M | 0.20M | 0.07M | 0.02M |
| Net interest income | 0.55M | 0.20M | 0.07M | 0.02M |
| Extraordinary items | - | - | - | - |
| Non recurring | - | - | - | - |
| Other items | - | - | - | - |
| Income tax expense | 6.23M | -3.98900M | 0.30M | 0.00200M |
| Total revenue | 0.23M | 20.38M | 0.00000M | 0.00000M |
| Total operating expenses | 144.66M | 140.70M | 92.14M | 8.17M |
| Cost of revenue | - | - | - | - |
| Total other income expense net | 9.61M | -0.79600M | 2.35M | -19.04800M |
| Discontinued operations | - | - | - | - |
| Net income from continuing ops | -141.41100M | -174.24400M | -178.62500M | -24.38400M |
| Net income applicable to common shares | -152.38500M | -167.80800M | -169.84300M | -14.13800M |
| Preferred stock and other adjustments | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 293.48M | 305.44M | 414.17M | 111.55M | 62.12M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 29.08M | 14.04M | 11.90M | 0.55M | 0.21M |
| Total liab | 49.16M | 300.42M | 405.12M | 16.18M | 2.48M |
| Total stockholder equity | 242.96M | 260.74M | -348.13700M | 90.82M | 58.75M |
| Deferred long term liab | - | - | - | 1.57M | - |
| Other current liab | 14.54M | 17.50M | 14.93M | 9.21M | 0.92M |
| Common stock | 18.57M | 18.56M | 18.00M | 13.37M | 10.51M |
| Capital stock | 18.57M | 18.56M | 18.00M | 13.37M | 10.51M |
| Retained earnings | -550.93800M | -510.18800M | -357.80300M | -189.99500M | -20.15200M |
| Other liab | - | 2.26M | 6.53M | 1.71M | 0.57M |
| Good will | - | - | - | - | - |
| Other assets | - | 10.61M | 11.18M | 3.88M | - |
| Cash | 45.03M | 190.61M | 362.27M | 97.25M | 30.06M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 20.12M | 19.90M | 20.93M | 12.30M | 1.61M |
| Current deferred revenue | 0.72M | - | - | - | - |
| Net debt | -28.55800M | -175.49600M | -361.52300M | -95.06900M | -29.90500M |
| Short term debt | 0.28M | - | - | - | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 16.48M | 15.12M | 0.74M | 2.18M | 0.16M |
| Other stockholder equity | 794.79M | 774.07M | 348.14M | 261.63M | 69.82M |
| Property plant equipment | - | 0.93M | 0.15M | 0.07M | 0.02M |
| Total current assets | 185.59M | 287.14M | 375.08M | 99.55M | 39.15M |
| Long term investments | 91.66M | 14.02M | 27.76M | 8.04M | 22.95M |
| Net tangible assets | - | 260.74M | 376.91M | 90.82M | 58.75M |
| Short term investments | 109.22M | 82.50M | - | - | - |
| Net receivables | 2.26M | 5.63M | 0.91M | 1.29M | 8.70M |
| Long term debt | 17.88M | 14.70M | 0.74M | 2.18M | 0.16M |
| Inventory | 0.00000M | - | - | 0.46M | 0.17M |
| Accounts payable | 4.59M | 2.40M | 6.00M | 3.08M | 0.69M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | 5.03M | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -19.46000M | -21.70200M | -8.33600M | 5.82M | -1.42600M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 18.56M | - | 13.37M | 10.51M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -510.18800M | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2.72M | 10.61M | 11.18M | 3.88M | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 107.89M | 18.30M | 39.08M | 12.00M | 22.97M |
| Capital lease obligations | 1.26M | - | - | - | - |
| Long term debt total | - | 14.70M | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -85.82400M | -81.27600M | -26.00800M | -1.23700M |
| Change to liabilities | -1.81300M | 2.31M | 1.70M | 0.25M |
| Total cashflows from investing activities | -86.84800M | -81.27600M | -28.27100M | -9.03100M |
| Net borrowings | 17.89M | 1.59M | 32.50M | 32.50M |
| Total cash from financing activities | 20.79M | 409.86M | 113.05M | 40.39M |
| Change to operating activities | -0.30100M | -9.91600M | 2.75M | -0.37500M |
| Net income | -157.41700M | -174.24400M | -178.62500M | -24.38400M |
| Change in cash | -171.65300M | 265.02M | 67.18M | 23.14M |
| Begin period cash flow | 362.27M | 97.25M | 30.06M | 6.92M |
| End period cash flow | 190.61M | 362.27M | 97.25M | 30.06M |
| Total cash from operating activities | -104.46700M | -63.24600M | -20.76600M | -7.84600M |
| Issuance of capital stock | 0.60M | 409.88M | 82.44M | 42.68M |
| Depreciation | 0.17M | 0.05M | 0.02M | 0.00600M |
| Other cashflows from investing activities | -0.25100M | -2.55300M | -2.20400M | -7.77500M |
| Dividends paid | - | - | - | - |
| Change to inventory | - | - | - | - |
| Change to account receivables | - | - | - | - |
| Sale purchase of stock | 2.29M | - | - | - |
| Other cashflows from financing activities | 16.15M | -0.02200M | 30.61M | -2.29500M |
| Change to netincome | 41.74M | 111.92M | 144.54M | 6.41M |
| Capital expenditures | 1.02M | 1.13M | 0.06M | 0.02M |
| Change receivables | -0.27200M | - | - | - |
| Cash flows other operating | 13.00M | - | - | - |
| Exchange rate changes | - | - | - | - |
| Cash and cash equivalents changes | -170.53000M | - | - | - |
| Change in working capital | -3.33500M | -7.60400M | 4.45M | -0.12600M |
| Stock based compensation | 42.38M | 63.36M | 67.16M | 0.06M |
| Other non cash items | 8.67M | 16.06M | 29.88M | 9.06M |
| Free cash flow | -105.49100M | -64.37400M | -20.82500M | -7.86500M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ATAI ATAI Life Sciences BV |
0.03 1.84% | 1.66 | - | - | 1216.11 | 1.57 | 706.20 | -6.1068 |
| NVO Novo Nordisk A/S |
-2.13 3.22% | 64.02 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-2.15 3.28% | 63.40 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-0.34 0.08% | 434.04 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
3.10 0.53% | 588.10 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.
Wallstrasse 16, Berlin, Germany, 10179
| Name | Title | Year Born |
|---|---|---|
| Mr. Christian Angermayer | Founder & Chairman of the Supervisory Board | 1978 |
| Mr. Florian Brand | Co-founder & CEO | 1987 |
| Dr. Srinivas G. Rao M.D., Ph.D. | Co-Founder & Chief Scientific Officer | 1969 |
| Dr. Rolando Gutierrez-Esteinou M.D. | Chief Medical Officer | 1961 |
| Mr. Gregory L. Weaver CPA, M.B.A. | Non-Employee Advisor | 1956 |
| Mr. Stephen B. Bardin | MD & CFO | 1990 |
| Mr. Frank Stegert | VP of Investment & Venture Management | 1981 |
| Ms. Anne Johnson | Chief Accounting Officer | NA |
| Ms. Madison Crawford | Sr. Mang. of Accounting | NA |
| Mr. Aaqil Anwar | Mang. of Corp. Fin. & Investor Relations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...